Gland B2B Business Model and Growth Strategy
Complex Product Portfolio Supported by Strong R&D...
Expertise in
synthesis of
complex drug
molecules:
Low Molecular
Weight Heparins
■ Steroids
27
27
Cytotoxics
Present in:
•
Right Capability Matrix in Products and Delivery Systems
Focused on:
■ Complex
injectables
Oncology
Ophthalmics and
Otologicals
Blood-related
Neurological and
Central Nervous
NCE-1s
Expanding
capabilities in:
Peptides
"
Long-acting
First-to-File
products
injectables
·
Suspensions
System
505(b)(2) filings
Hormonal products
•
Pain, neuro-muscular
agents and
" Biosimilar
Expanding in new
delivery systems:
☐
Pens
Cartridges
Key products
include:
Cis-Atracurium
Besylate
Enoxaparin Sodium
Heparin Sodium
■ Rocuronium
Bromide
analgesics
Significant R&D Investment
Translating into Revenue From New Launches
Centralized R&D team of c.268 members including PhDs, pharmacy post
graduates and chemists
Track record of coming up with new complex products
3.8%
4.7%
3.5%
3.5%
22%
13%
9%
11%
1,220
966
922
45
51
57
615
3,493
3,660
2,717
2,292
FY18
FY19
FY20
■Total R&D expenditure (mn)
R&D expenditure as % of revenue from operations
FY21
FY18
FY19
FY20
FY21
■Revenue from new product launch (mn)
As % of revenue from operations
#products launched
GLANDView entire presentation